DS1062-A-U303/ TROPION-Lung07

A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

Open at Paris since : 08/10/2024
Target : Adult
Phase : Phase III

Trial description

To compare the efficacy of;Dato-DXd in combination;with pembrolizumab with or;without platinum-based;chemotherapy versus;pembrolizumab plus;pemetrexed and platinumbased;chemotherapy, as;measured by Progression-;Free Survival (PFS) by;blinded independent central;review (BICR).;To compare the efficacy of;Dato-DXd in combination;with pembrolizumab with or;without platinum-based;chemotherapy versus;pembrolizumab plus;pemetrexed and platinumbased;chemotherapy, as;measured by Overall;Survival (OS)

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact